GlassScriptPhysician profile
Selene K Bantz
NPI 1619111366
$2,410.65
in general payments reported to CMS, 2019-2025
16 companies · $69.66 in 2025
The $69.66 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,052 · 2020: $289 · 2025: $69.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $610.30 | 2019-2020 | |
| Glaxosmithkline, LLC. | $525.97 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $323.88 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $220.44 | 2019-2020 | |
| Alk-Abello, INC | $176.42 | 2019-2020 | |
| Optinose US, INC. | $158.74 | 2019-2020 | |
| Genzyme Corporation | $105.91 | 2019-2025 | |
| Kaleo, INC. | $48.13 | 2019 | |
| Pfizer INC. | $46.80 | 2019-2020 | |
| Csl Behring | $42.50 | 2019 | |
| Shire North American Group INC | $36.44 | 2019 | |
| Circassia INC. | $36.02 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.46 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.28 | 2020 | |
| Genentech USA, INC. | $17.72 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $16.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Selene Bantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.